Skip to main content

MINI REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1528957

Cutaneous metastasis of squamous cervical carcinoma: complete regression after molecular diagnosis

Provisionally accepted
Liwen Guo Liwen Guo 1Yanqiong Liu Yanqiong Liu 1Shuhua Zhang Shuhua Zhang 2*Wei Liu Wei Liu 1,3*
  • 1 Hunan Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, China
  • 2 Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China
  • 3 Department of Pathology, Hunan Cancer Hospital, Changsha, Hunan Province, China

The final, formatted version of the article will be published soon.

    Common metastasis sites for cervical cancer are the lungs, bones, liver, brain, ovaries, and lymph nodes, among other sites. Skin metastasis is very uncommon, and is only observed in approximately 1% of patients. The cancer spreads typically through lymphatic or blood vessels, but a definitive example of lymphatic spread has not been documented thoroughly in the existing literature. Cutaneous metastasis may be confused with cellulitis or a rash; hence, an immediate cutaneous biopsy of any suspicious lesions is recommended. There is no consensus regarding the treatment of this condition. Only one documented case has shown that a combination of paclitaxel, carboplatin, bevacizumab, and zoledronic acid can lead to a complete metabolic response. Our study, which used two cycles of albumin-bound paclitaxel, cisplatin, and bevacizumab, followed by four cycles of the same regimen plus terprelimab for metastases with CPS scores of Programmed death-ligand 1 (PD-L1) over 10, resulted in a stable complete response for over eight months. Our contribution may assist in formulating effective treatment guidelines for the cutaneous metastasis of squamous cervical carcinoma in the future.

    Keywords: Cutaneous metastasis, Cervical carcinoma, prognosis, complete response, immunochemotherapy, Molecular diagnosis

    Received: 15 Nov 2024; Accepted: 26 Dec 2024.

    Copyright: © 2024 Guo, Liu, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shuhua Zhang, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan Province, China
    Wei Liu, Hunan Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.